<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="9425"><DrugName>9-aminocamptothecin</DrugName><DrugSynonyms><Name><Value>9-amino-20 (S)-camptothecin</Value></Name><Name><Value>9-aminocamptothecin</Value></Name><Name><Value>NSC-603071</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>9-AC</Value></Name><Name><Value>91421-43-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23125">RTI International</CompanyOriginator><CompaniesSecondary><Company id="17085">IDEC Pharmaceuticals Corp</Company><Company id="20519">National Cancer Institute</Company><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Company id="23125">RTI International</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9425" type="Drug"><TargetEntity id="184764" type="siDrug">9-Aminocamptothecin</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="22006" type="Company"><TargetEntity id="5036162624" type="organizationId">Pharmacia &amp; Upjohn LLC</TargetEntity></SourceEntity><SourceEntity id="23125" type="Company"><TargetEntity id="4295987093" type="organizationId">Research Triangle Institute</TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"></TargetEntity><TargetEntity id="D007938" type="MeSH"></TargetEntity><TargetEntity id="-609576380" type="omicsDisease"></TargetEntity><TargetEntity id="683" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="42" type="ciIndication"><TargetEntity id="10005056" type="MEDDRA"></TargetEntity><TargetEntity id="D001749" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="54" type="ciIndication"><TargetEntity id="D002277" type="MeSH"></TargetEntity><TargetEntity id="-233893258" type="omicsDisease"></TargetEntity><TargetEntity id="665" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="623" type="ciIndication"><TargetEntity id="C76.0" type="ICD10"></TargetEntity><TargetEntity id="10067821" type="MEDDRA"></TargetEntity><TargetEntity id="D006258" type="MeSH"></TargetEntity><TargetEntity id="-545944758" type="omicsDisease"></TargetEntity><TargetEntity id="1148" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"></TargetEntity><TargetEntity id="10038389" type="MEDDRA"></TargetEntity><TargetEntity id="D007680" type="MeSH"></TargetEntity><TargetEntity id="-1866040075" type="omicsDisease"></TargetEntity><TargetEntity id="607" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="141" type="Action"><TargetEntity id="418" type="Mechanism">DNA Topoisomerase I Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01877" type="ciTarget"><TargetEntity id="133883360" type="siTarget">DNA topoisomerase</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="127">Stomach tumor</Indication><Indication id="199">Leukemia</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="276">Prostate tumor</Indication><Indication id="42">Bladder tumor</Indication><Indication id="54">Carcinoma</Indication><Indication id="623">Head and neck tumor</Indication><Indication id="651">Cancer</Indication><Indication id="755">Lung tumor</Indication><Indication id="989">Colorectal tumor</Indication><Indication id="999">Renal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="141">Topoisomerase I inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="630">Stereochemistry</Technology></Technologies><LastModificationDate>2018-01-07T11:28:41.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;The &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; (NCI) was developing &lt;ulink linkID="9425" linkType="Drug"&gt;9-aminocamptothecin&lt;/ulink&gt; (9-AC; structure shown), a topoisomerase I inhibitor discovered by &lt;ulink linkID="23125" linkType="Company"&gt;Research Triangle Institute&lt;/ulink&gt; [&lt;ulink linkID="196455" linkType="reference"&gt;196455&lt;/ulink&gt;], for the potential treatment of cancer. It has undergone phase II trials in the US for the potential treatment of solid tumors unresponsive to other therapy. It was also under development by the NCI in collaboration with &lt;ulink linkID="18995" linkType="Company"&gt;Pharmacia &amp;amp; Upjohn&lt;/ulink&gt; (P&amp;amp;U), and worldwide rights were sold to IDEC Pharmaceuticals in July 1997 [&lt;ulink linkID="256205" linkType="reference"&gt;256205&lt;/ulink&gt;]. In July 1999, IDEC terminated development of 9-AC following the results of a phase II trial which did not indicate that the product would be superior to existing therapies [&lt;ulink linkID="333721" linkType="reference"&gt;333721&lt;/ulink&gt;]. However, in April 2002, it was reported that 9-AC had undergone a phase I trial in patients with intraperitoneal malignancies with the &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; and &lt;ulink linkID="24282" linkType="Company"&gt;Albert Einstein College of Medicine&lt;/ulink&gt; [&lt;ulink linkID="446587" linkType="reference"&gt;446587&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2003, clinical data on 9-AC were presented at the 39th ASCO meeting in Chicago, IL. In a multicenter, phase II trial, patients (n = 58) with recurrent platinum-resistant or refractory ovarian cancer were given 9-AC (25 microg/m2/h iv) over 120 h on days 1 and 8 in a 21-day cycle. The cycle was repeated until toxicity occurred or disease progressed. The median number of courses was four and the most common grade 3 and 4 adverse events were neutropenia, leukopenia, anemia and thrombocytopenia. One patient death was possibly related to the drug. Of the 58 patients, 4 had a complete response, 4 had a partial response, 18 had stable disease and 22 progressed [&lt;ulink linkID="491633" linkType="reference"&gt;491633&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2002, data from a phase I trial with 9-AC were presented at the 93rd AACR meeting in San Francisco, CA. In 12 patients with tumors in the abdominal cavity, 9-AC was administered in six fractions over 12 days at five ip dose levels: 1.25, 2.5, 6, 9 and 13.5 mg/m2. At the maximum tolerated dose, 0.9 mg/m2, 9-AC was efficacious in its antitumor activity with tolerable toxicity [&lt;ulink linkID="446587" linkType="reference"&gt;446587&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 1999, IDEC terminated development of 9-AC following the results of a phase II trial involving patients with one of eight solid tumor types [&lt;ulink linkID="333721" linkType="reference"&gt;333721&lt;/ulink&gt;]. In May 2000, the termination of this phase II trial was described at the 36th ASCO meeting in New Orleans, LA, after no clinical responses but significant toxicities were observed in 69 patients treated with dosing to achieve pharmacokinetic targets [&lt;ulink linkID="369845" linkType="reference"&gt;369845&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 1997, a phase II study of second line therapy of patients with advanced ovarian cancer was underway at the Allegheny Cancer Center [&lt;ulink linkID="243050" linkType="reference"&gt;243050&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II trial and dose escalation study of 9-AC, with and without G-CSF, in relapsed/incurable lymphoma was completed. The drug was administered by 72-h continuous infusion every 3 weeks. Results show that 9-AC was active in heavily pretreated patients with lymphoma. Thrombocytopenia was often dose-limiting and prevented significant dose escalation even with G-CSF support. It was suggested that the drug should be studied in less heavily pretreated patients [&lt;ulink linkID="203879" linkType="reference"&gt;203879&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II trial of 9-AC in advanced non-small cell lung cancer (NSCLC) was carried out. Results showed that a 9-AC dose of 1100 microg/m2/day x 3 was well tolerated in the majority of patients, and that the drug had activity in NSCLC. Neutropenia was the dose-limiting toxicity and appeared to be well correlated with estimated free 9-AC. Separate quantitation of the lactone did not appear to be necessary for pharmacodynamic studies [&lt;ulink linkID="203876" linkType="reference"&gt;203876&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1997, IDEC initiated a phase I/II clinical trial of 9-AC, aimed at seeking an initial indication to pursue for marketing approval. The trial was to include patients with any one of eight solid tumor types: non-small-cell lung, colorectal, pancreatic, gastric, bladder, prostate, head and neck, or kidney [&lt;ulink linkID="269710" linkType="reference"&gt;269710&lt;/ulink&gt;]. The phase I part of the study was an escalating-dose safety study of 9-AC in nine patients. Once the maximum-tolerated dose was confirmed, more patients were to be enrolled in phase IIa of the study in each of the eight targeted tumor types. If the investigators identifed one response in any tumor type, additional patients with that cancer were to be studied in phase IIb of the trial to determine an estimate of the response rate for that disease. Once the investigators identifed a meaningful response rate for one or more tumor types, IDEC intended to choose one of those indications to take into a phase III pivotal study [&lt;ulink linkID="269710" linkType="reference"&gt;269710&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preclinical and phase I/II clinical studies have been conducted by P&amp;amp;U and by the &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt;, showing clinical activity against a variety of solid tumors [&lt;ulink linkID="269710" linkType="reference"&gt;269710&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase I trial results from 18 chemotherapy-naive solid tumor patients were presented at the 35th ASCO meeting in May 1999. The data indicated that the infusion of 9-AC led to neutropenia, neutropenic sepsis, anemia, alopecia and vomiting. The recommended phase II dose was to be set at either 1.3 or 1.5 mg/m2/day [&lt;ulink linkID="327437" linkType="reference"&gt;327437&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results of a phase I trial in patients with solid tumors were presented at the 90th AACR meeting. Patients were given 0.9 to 1.8 mg/m2/day for 5 consecutive days on a 21-day schedule. Based on the responses seen, the authors suggested a new dosing regime for phase II trials (1.3 mg/m2/day x 5) [&lt;ulink linkID="321936" linkType="reference"&gt;321936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1998, results of a 39-patient phase I study of 9-AC colloidal dispersion formulation in patients with refractory or relapsed acute leukemia were presented at the 40th ASH meeting in Miami, FL [&lt;ulink linkID="308842" linkType="reference"&gt;308842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I pharmacokinetic study, looking at a daily times five iv bolus dose of 9-AC, was presented at the 1998 ASCO meeting. The study confirmed that the regimen was 'safe and feasible', that the dose limiting toxicity was myelosuppression, that kinetics were markedly variable between patients, and that a recommended dose for a phase II trial would be 1.1 mg/m2/day for both heavily, and minimally pretreated patients [&lt;ulink linkID="288791" linkType="reference"&gt;288791&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I study in 59 patients with high grade astrocytomas showed that higher than usual doses of chemotherapy may be needed in those patients taking concommitant anticonvulsants [&lt;ulink linkID="273402" linkType="reference"&gt;273402&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I trial of 9-AC in children with solid tumors refractory to conventional treatment has been conducted. The starting dose of 9-AC was 36 microg/m2/h for 72 h every 3 weeks, which is 80% of the adult MTD. Doses were escalated by 20% increment with at least 3 patients per cohort. The first course of therapy was to determine the dose-limiting toxicity and MTD. A total of 18 patients had been entered. Results from the study have shown that myelosuppression is the most likely dose-limiting toxicity. The MTD remained to be defined in this trial but clearly the adult MTD without G-CSF had been exceeded. The pharmacokinetics of 9-AC were extremely variable, and the relationship between the plasma drug concentrations and activity or toxicity required further study [&lt;ulink linkID="203874" linkType="reference"&gt;203874&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Studies synthesising several 5-substituted alkoxy 20(S)-camptothecin analogs, posessing A-and B-ring substituents, were found to exhibit potent anticancer activity based on their in vitro cytotoxicity data, obtained against human tumor cell lines [&lt;ulink linkID="370595" linkType="reference"&gt;370595&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;9-AC induces the release of mitochondrial cytochrome c into the cytoplasm to trigger apoptosis [&lt;ulink linkID="283676" linkType="reference"&gt;283676&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;&lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt; had inlicensed 9-aminocamtpthecin from the &lt;ulink linkID="23125" linkType="Company"&gt;Research Triangle Institute&lt;/ulink&gt; by 1994 [&lt;ulink linkID="176922" linkType="reference"&gt;176922&lt;/ulink&gt;]. In July 1997, worldwide rights were transferred  by &lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt; to IDEC Pharmaceuticals [&lt;ulink linkID="233746" linkType="reference"&gt;233746&lt;/ulink&gt;], [&lt;ulink linkID="256205" linkType="reference"&gt;256205&lt;/ulink&gt;]. In July 1999, IDEC terminated development of 9-AC [&lt;ulink linkID="333721" linkType="reference"&gt;333721&lt;/ulink&gt;]. By April 2002, the NCI was conducting phase I trials on 9-AC [&lt;ulink linkID="446587" linkType="reference"&gt;446587&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;For some decades, the &lt;ulink linkType="Company" linkID="20519"&gt;National Cancer Institute&lt;/ulink&gt; has been interested in screening natural products for their anti-tumor activities. One such natural product, camptothecin, was originally isolated from the wood and wood bark extract of a Chinese tree, Camptotheca acuminata, a member of the Nyssaceae family. The compound was found to be active against murine leukemia cell line L1210. Despite promising findings in animal studies, camptothecin failed to induce durable responses in the majority of patients in early phase I and II clinical trials and therefore interest in it ceased by 1970. A large number of analogs of camptothecin were then synthesized [&lt;ulink linkType="reference" linkID="196455"&gt;196455&lt;/ulink&gt;]. Several, including 9-nitrocamptothecin (9-NC), &lt;ulink linkType="Drug" linkID="9425"&gt;9-aminocamptothecin&lt;/ulink&gt; (9-AC), CPT-11 and &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt; are in various stages of preclinical and clinical evaluation and have shown activity against several solid tumors which are refractory to other forms of treatments. 9-AC is undergoing extensive clinical evaluation in cancer patients refractory to established treatments [&lt;ulink linkType="reference" linkID="196456"&gt;196456&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="208431"&gt;208431&lt;/ulink&gt;] &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mechanism of action of camptothecin&lt;/subtitle&gt;One of the reasons for renewed interest in camptothecin and its analogs was the discovery in the mid 1980s that they inhibit the action of topoisomerase I, an enzyme implicated in various DNA events such as replication, transcription and recombination in cultured mammalian cells. It is a monomeric protein encoded by a single-copy gene on chromosome 20q12-13.2 [&lt;ulink linkType="reference" linkID="196661"&gt;196661&lt;/ulink&gt;]. Unlike topoisomerase II which can cleave both strands of DNA, topoisomerase I cleaves only a single strand. The eukaryotic form of topoisomerase I is highly conserved and its inhibition leads to accumulation of DNA strand breaks and ultimate cell death [&lt;ulink linkType="reference" linkID="196659"&gt;196659&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="208429"&gt;208429&lt;/ulink&gt;]. The mechanism involves a transient breakage of one of the two DNA strands and formation of a covalent topoisomerase I-DNA complex. Camptothecins act by reversibly trapping this cleavable complex. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The structural features required for enzyme inhibition are the alpha-hydroxy-delta-lactone moiety that constitutes E ring, the tertiary alcohol and S-configuration at the chiral center at position 20 [&lt;ulink linkType="reference" linkID="196610"&gt;196610&lt;/ulink&gt;]. The structural basis of the interaction between camptothecins and human serum albumin (HSA) has been investigated [&lt;ulink linkType="reference" linkID="155405"&gt;155405&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="208443"&gt;208443&lt;/ulink&gt;]. Alpha-hydroxy-delta-lactone ring moiety of camptothecin and its derivatives is hydrolyzed more rapidly and completely in the presence of HSA. HSA binds preferentially to the carboxylate form over the lactone form. Specific modifications at the 7- and 9- positions of the quinoline nucleus enhance drug stability in the presence of HSA, presumably due to preferential associations between the lactone form and the blood protein. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical studies &lt;/subtitle&gt;A mutant human topoisomerase I with intact catalytic activity and resistance to inhibition by 9-NC has been identified [&lt;ulink linkType="reference" linkID="196567"&gt;196567&lt;/ulink&gt;]. Myeloid leukemia cells (U-937) were selected for resistance to 9-NC. Topoisomerase I gene expression in these cells demonstrated mRNA levels similar to those found in the parent cells. Nucleotide sequencing of the enzyme cDNAs revealed substitution of phenylalanine at residue 361 with serine in the 9-NC-resistant cells. These findings support the involvement of the catalytic region in the interaction between the enzyme and 9-NC. &lt;/para&gt;&lt;para&gt;Several water-soluble camptothecin derivatives have been tested for their ability to inhibit growth of human melanoma tumors xenografted in nude mice [&lt;ulink linkType="reference" linkID="196604"&gt;196604&lt;/ulink&gt;]. Anti-tumor activity was found to be dependent on the derivative, dose, mode of administration and scheduling. Oral administration of 9-NC produced the best overall results. &lt;/para&gt;&lt;para&gt;The effects of liposome-incorporated camptothecin (LCPT) on human malignant xenografts in nude mice have been investigated [&lt;ulink linkType="reference" linkID="196560"&gt;196560&lt;/ulink&gt;]. A single injection of 10 mg of LCPT im displayed effective anti-tumor activity against malignant melanoma and breast carcinoma, with minimal host toxicity. The data suggest that im administration of the drug to patients with lymph node metastases might induce effective control of tumor growth. &lt;/para&gt;&lt;para&gt;The ability of camptothecins to distinguish between non-tumorigenic and tumorigenic cells in the induction of regression of human ovarian carcinomata grown in nude mice has been investigated [&lt;ulink linkType="reference" linkID="171405"&gt;171405&lt;/ulink&gt;]. Both 9-NC and 9-AC effectively inhibit growth and induce regression of tumor growth. In vitro, 9-NC-induced growth inhibition of non-tumorigenic cells was associated with accumulation of these cells in G2 phase of the cell cycle, whereas in tumorigenic cells it was associated with generation of cells with a reduced DNA content. Thus camptothecins appear to be cytostatic for non-tumorigenic cells and cytotoxic for tumorigenic cells. Similar findings have been reported for the inhibition of growth of U-937 leukemia tumors and human myelomonocytic leukemia cell lines [&lt;ulink linkType="reference" linkID="171406"&gt;171406&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Tanizawa et al [&lt;ulink linkType="reference" linkID="196577"&gt;196577&lt;/ulink&gt;] compared topoisomerase I inhibition, DNA damage and cytotoxicity of 9-AC, &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;, CPT-11 and its metabolite SN-38 in human colon carcinoma HT-29 cells. These data showed SN-38 to be the most potent and CPT-11 the least potent compounds and therefore the clinical activity of CPT-11 may depend on its hydrolysis to SN-38. &lt;/para&gt;&lt;para&gt;The hydrolysis of 9-AC and its 10,11-methylenedioxy derivative in mice were investigated [&lt;ulink linkType="reference" linkID="196610"&gt;196610&lt;/ulink&gt;] by measurement of the ratio of intact lactone and opened ring carboxylate forms. The apparent volume of distribution () for 9-AC was 7.7 l/kg and the terminal phase half-life (t(1/2)z) 1.4 hours. The Vz for 10,11-dimethylenedione derivative was 694 l/kg and the t(1/2)z 15.2 h. Thus, 9-AC appears to be cleared from circulation much faster than the 10,11-dimethylenedione derivative. &lt;/para&gt;&lt;para&gt;The transport properties of camptothecin derivatives across cellular membranes of multidrug resistant KB carcinoma cell line (KB V1) were investigated by Chen et al [&lt;ulink linkType="reference" linkID="32926"&gt;32926&lt;/ulink&gt;]. Multidrug resistance overexpression in these cells did not prevent the cytotoxic action of uncharged derivatives such as 9-AC or 10,11-methylenedioxy-camptothecin. &lt;ulink linkType="Drug" linkID="4577"&gt;Topotecan&lt;/ulink&gt;, however, showed reduced cytotoxicity, indicating that the charge on the derivative can affect its sensitivity to multidrug resistance. &lt;/para&gt;&lt;para&gt;Cross-resistance to various camptothecin analogs in a &lt;ulink linkType="Drug" linkID="11519"&gt;mitoxantrone&lt;/ulink&gt;-resistant human breast cancer cell line (MCF7/MX) was examined [&lt;ulink linkType="reference" linkID="196449"&gt;196449&lt;/ulink&gt;]. This cell line was found to be cross-resistant to all the analogs with varied resistance (&lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;: 180-fold, camptothecin: 3.2-fold). &lt;ulink linkType="Drug" linkID="11519"&gt;Mitoxantrone&lt;/ulink&gt;-sensitive and -resistant cell lines contained equal amounts of DNA topoisomerase protein and had equal DNA relaxation activities which were inhibited to the same extent by &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt; and camptothecin. The data indicate that cross-resistance is not due to DNA topoisomerase I alterations. &lt;/para&gt;&lt;para&gt;Xenograft models of malignant melanoma, lung squamous carcinoma, lymphoblastoid cells (CNS) and colon adenocarcinoma (liver) have been developed [&lt;ulink linkType="reference" linkID="196448"&gt;196448&lt;/ulink&gt;].  9-AC, injected im or delivered via the gastrointestinal tract, inhibited the growth of CNS and liver metastases and increased survival of treated animals. Such models should help to speed up drug screening processes. &lt;/para&gt;&lt;para&gt;Since significantly higher concentrations of topoisomerase I were found in advanced colon carcinoma than in normal colonic mucosa, the effects of 9-AC on the carcinoma xenografted in nude mice were examined. It was found that 9-AC induced disease-free remissions [&lt;ulink linkType="reference" linkID="171407"&gt;171407&lt;/ulink&gt;]. The overall toxicity was low and allowed for repeated courses of treatment. These studies were responsible for confirming the anti-tumor activity of 9-AC in this carcinoma. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical evaluation&lt;/subtitle&gt;The pharmacokinetics of conversion of 9-NC to 9-AC in humans has been investigated [&lt;ulink linkType="reference" linkID="196565"&gt;196565&lt;/ulink&gt;]. After a single dose of 9-NC (0.1 mg/kg), the maximum calculated conversion to 9-AC was 14 ng/ml at 10.3 h, with an AUC of 311 ng.h/ml and a half-life of 7.1 h. Following a higher dose of 9-NC (1.0 mg/kg), values for the same parameters were: 208 ng/ml at 17.2 h, 9121 ng.h/ml and 13.1 h respectively. &lt;/para&gt;&lt;para&gt;Chemosensitivity of lymphocytes from 65 patients with B-cell chronic lymphocytic leukemia (B-CLL) to camptothecin analogues was investigated by Silber et al [&lt;ulink linkType="reference" linkID="196563"&gt;196563&lt;/ulink&gt;]. 52 and 67% of chlorambucil-resistant lymphocyte samples were sensitive to 10,11-methylenedioxy-20(S)-camptothecin and 9-amino-10,11-methylenedioxy-20(S)-camptothecin respectively, thereby indicating a possible role for these analogues in the management of patients with B-CLL. &lt;/para&gt;&lt;para&gt;A phase I and pharmacologic study of a 72 hour 9-AC infusion with doses ranging from 5-59 microg/m2/h, with or without granulocyte colony-stimulating factor (G-CSF), was carried out in 95 patients with solid tumors [&lt;ulink linkType="reference" linkID="208428"&gt;208428&lt;/ulink&gt;]. Two patients each at 47 and 59 microg/m2/hour dose levels, without G-CSF, had dose-limiting neutropenia in their initial cycle. In the group treated with G-CSF, 6/14 patients had similar toxicity at a dose level of 59 microg/m2/hour. Other toxicities such as fatigue, diarrhea and nausea/vomiting were noted in half the patients in both the groups. Doses of 35 and 47 microg/m2/hour every two weeks without and with G-CSF respectively were recommended for a phase II trial. The addition of G-CSF appears to increase the tolerance of patients to higher doses. &lt;/para&gt;&lt;para&gt;A similar phase I evaluation of 9-AC was undertaken by Rubin et al [&lt;ulink linkType="reference" linkID="177151"&gt;177151&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="196584"&gt;196584&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="208435"&gt;208435&lt;/ulink&gt;]. Thirty one patients with solid tumors were treated with a 72 hour continuous infusion of 9-AC (5-60 microg/m2/h) repeated at three week intervals. The maximum tolerated dose (MTD) was determined to be 45 microg/m2/h and dose-limiting toxicities consisted of neutropenia and thrombocytopenia. There were minimal responses in patients with gastric, colon and non-small cell lung cancer. In a study on 18 children with refractory solid tumors treated with 9-AC (36-62 microg/m2/hour x 72 hours every three weeks) [&lt;ulink linkType="reference" linkID="203874"&gt;203874&lt;/ulink&gt;], myelosuppression was the dose-limiting factor. &lt;/para&gt;&lt;para&gt;A phase I trial has been carried out in 19 patients with slightly altered protocol in which 9-AC was administered at a dose of 149 microg/m2/d for seven days and escalated the duration of infusion to 21 days every 28 days [&lt;ulink linkType="reference" linkID="203872"&gt;203872&lt;/ulink&gt;]. Preliminary results show that the administration of the same quantity of drug but over a longer period has resulted in the absence of hematologic toxicities. &lt;/para&gt;&lt;para&gt;A phase II trial of 9-AC in 26 patients with advanced non-small cell lung cancer showed that there was a very high incidence of neutropenia and thrombocytopenia in 13 patients treated with 59 microg/m2/h [&lt;ulink linkType="reference" linkID="203876"&gt;203876&lt;/ulink&gt;]. The remaining 13 patients were treated with a reduced dose of 45 microg/m2/h. Overall, 3/23 patients had partial response to the treatment and the low response rate was accompanied by severe hematological toxicities. &lt;/para&gt;&lt;para&gt;A similar study of 9-AC was carried out in 36 relapsed lymphoma patients, 21 of whom also received G-CSF [&lt;ulink linkType="reference" linkID="203879"&gt;203879&lt;/ulink&gt;]. Patients were initially treated with 40 microg/m2/h every 72 h and the dose was escalated by 10 microg/m2/h each cycle if acceptable hematologic and non-hematologic toxicities were observed. Of the 30 evaluable patients, 9 achieved partial responses of 1-10.5 months duration. Thrombocytopenia was dose-limiting and prevented significant dose escalation even with G-CSF support. The results of these two phase II trials clearly show the limitations placed on the use of 9-AC in relapsed patients with various malignancies. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Preclinical research on camptothecins in the past two decades has been more rewarding since its role as a specific DNA topoisomerase I inhibitor was established. It has given molecular and cell biologists excellent opportunity to investigate mechanisms underlying both malignant cell growth and apoptosis. Questions must be asked regarding the rewards for such efforts and whether an effective role for any of the camptothecin analogs in the management of human malignancies has really been established. &lt;/para&gt;&lt;para&gt;As is the case with many new drugs undergoing evaluations, scientists working with malignant cell lines and others who have experimented with xenografts of various tumors in nude mice have produced the most convincing data on the anti-tumor activity of these compounds. Although there were wide variations in these activities between various analogs and between carcinomata from different sites, the literature has shown that at least one analog has shown activity against hematological, gynecological, breast and colorectal tumors. These findings have aroused the interest of many clinicians who were keen to treat patients who had either relapsed following standard therapies for their malignancies, or were not responding to them. However, since preclinical evaluations have failed to show overwhelming preference for a particular analog, that choice has been left with the clinician. For example, in preclinical investigations, orally administered 9-NC was found to be most effective in inhibiting tumor growth, but as yet, there are no clinical trials in which these findings have been tested. 9-AC, which has shown intermediate anti-tumor activity in preclinical studies, has undergone extensive clinical evaluation but is likely to be superseded by other analogs such as &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;, CPT-11 or its active metabolite SN-38. &lt;/para&gt;&lt;para&gt;The data so far acquired from phase I or phase II trials of 9-AC are inconclusive. In phase I trials, the MTD for 9-AC was not determined with reasonable accuracy. This has meant that these patients were probably treated with sub-optimal doses and even then, 9-AC produced grade III or IV hematologic toxicities. Whether simultaneous administration of G-CSF will significantly reduce the occurrence of adverse effects remains to be proven. Because of its comparatively short plasma half-life, 9-AC has to be administered through continuous infusion for several days per cycle. This has direct bearing on its cost-effectiveness when the patient is hospitalized for both treatment and while overcoming the effects of toxicities. A lower dose 21 day continuous infusion protocol has been proposed, which appears to have overcome the problem but has increased additional costs due to longer hospitalization. All this would have been a worthwhile exercise if the treatment produced durable responses in a fairly large proportion of treated patients, but so far, of the small number of patients investigated in phase II trials, the partial response rate has been 20-30%. Combined with the response duration of few weeks these results indicate that, unless patients are selected on the basis of some prognostic parameters, treatment with 9-AC will be probably not be cost-effective and the only basis for its inclusion is the lack of better alternatives. Therefore clinical trials currently being completed will finally determine the fate of 9-AC. &lt;/para&gt;&lt;para&gt;In conclusion, the impressive findings from preclinical evaluation of 9-AC have not been confirmed so far in clinical trials. Severe hematologic toxicities coupled with long stay in the hospital and poor response rates indicate that, unless future investigations show improvements in these observations, 9-AC will probably have only a limited role in the management of patients with hematologic and non-hematologic malignancies. This should not alter its usefulness in the investigation into the basic mechanism(s) associated with malignant cell growth or apoptosis. &lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="999">Renal tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="42">Bladder tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="127">Stomach tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="54">Carcinoma</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="199">Leukemia</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="651">Cancer</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate>1999-07-23T00:00:00.000Z</StatusDate><Source id="333721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2008-08-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="54">Carcinoma</Indication><StatusDate>1997-02-13T00:00:00.000Z</StatusDate><Source id="233746" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23125">RTI International</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="54">Carcinoma</Indication></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="54">Carcinoma</Indication><StatusDate>1994-12-01T00:00:00.000Z</StatusDate><Source id="176922" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate>1998-12-21T00:00:00.000Z</StatusDate><Source id="308842" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><Source id="177151" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23125">RTI International</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="54">Carcinoma</Indication><Source id="190994" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>2002-04-09T00:00:00.000Z</StatusDate><Source id="446587" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="42">Bladder tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="127">Stomach tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate>1997-11-19T00:00:00.000Z</StatusDate><Source id="269710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17085">IDEC Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="54">Carcinoma</Indication><StatusDate>1997-02-13T00:00:00.000Z</StatusDate><Source id="233746" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01877"><Name>Topoisomerase I</Name><SwissprotNumbers><Swissprot>O27661</Swissprot><Swissprot>O28469</Swissprot><Swissprot>O34204</Swissprot><Swissprot>O51768</Swissprot><Swissprot>O58356</Swissprot><Swissprot>O66893</Swissprot><Swissprot>O69548</Swissprot><Swissprot>O73954</Swissprot><Swissprot>O83409</Swissprot><Swissprot>P04786</Swissprot><Swissprot>P06612</Swissprot><Swissprot>P07799</Swissprot><Swissprot>P0A2I1</Swissprot><Swissprot>P0A2I2</Swissprot><Swissprot>P0A621</Swissprot><Swissprot>P11387</Swissprot><Swissprot>P16472</Swissprot><Swissprot>P30181</Swissprot><Swissprot>P30189</Swissprot><Swissprot>P32989</Swissprot><Swissprot>P34184</Swissprot><Swissprot>P34185</Swissprot><Swissprot>P39814</Swissprot><Swissprot>P40114</Swissprot><Swissprot>P41511</Swissprot><Swissprot>P41512</Swissprot><Swissprot>P43012</Swissprot><Swissprot>P46155</Swissprot><Swissprot>P46799</Swissprot><Swissprot>P47368</Swissprot><Swissprot>P55991</Swissprot><Swissprot>P57371</Swissprot><Swissprot>P68697</Swissprot><Swissprot>P68698</Swissprot><Swissprot>P73810</Swissprot><Swissprot>P78032</Swissprot><Swissprot>P83247</Swissprot><Swissprot>P93119</Swissprot><Swissprot>Q00313</Swissprot><Swissprot>Q04750</Swissprot><Swissprot>Q07050</Swissprot><Swissprot>Q1RIM1</Swissprot><Swissprot>Q4UM42</Swissprot><Swissprot>Q59046</Swissprot><Swissprot>Q68X45</Swissprot><Swissprot>Q76ZS7</Swissprot><Swissprot>Q7YR26</Swissprot><Swissprot>Q87AQ6</Swissprot><Swissprot>Q8K9P7</Swissprot><Swissprot>Q92IH1</Swissprot><Swissprot>Q9CG80</Swissprot><Swissprot>Q9CN30</Swissprot><Swissprot>Q9HM08</Swissprot><Swissprot>Q9HZJ5</Swissprot><Swissprot>Q9JN65</Swissprot><Swissprot>Q9KA23</Swissprot><Swissprot>Q9KRB2</Swissprot><Swissprot>Q9PEV8</Swissprot><Swissprot>Q9PLZ2</Swissprot><Swissprot>Q9UYS8</Swissprot><Swissprot>Q9WUL0</Swissprot><Swissprot>Q9X3X7</Swissprot><Swissprot>Q9X909</Swissprot><Swissprot>Q9YB01</Swissprot><Swissprot>Q9ZDK2</Swissprot><Swissprot>Q9ZMV7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005244">Biogen Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5cccc(c5c4)N)O</Smiles></StructureSmiles><Deals><Deal id="115406" title="IDEC to develop Pharmacia &amp; Upjohn's 9-AC worldwide"/><Deal id="115407" title="NCI and Pharmacia &amp; Upjohn to research 9-AC"/></Deals><PatentFamilies><PatentFamily id="1204577" number="WO-09509169" title="Process for the preparation of 9-amino camptothecin."/><PatentFamily id="127354" number="EP-02098533" title="Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy"/><PatentFamily id="1310775" number="WO-2007075492" title="Lipophilic anticancer drug compounds"/><PatentFamily id="256929" number="WO-2007075825" title="Lipophilic di(anticancer drug) compounds, compositions, and related methods"/><PatentFamily id="271741" number="WO-00128542" title="Combination Therapy Including Camptothecin"/><PatentFamily id="689931" number="WO-00061187" title="Radioenhanced cancer treatment using orally administered camptothecin derivatives"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="RTI International" id="23125"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>